{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T21:57:37Z","timestamp":1768341457267,"version":"3.49.0"},"reference-count":61,"publisher":"e-Century Publishing Corporation","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Transl Res"],"DOI":"10.62347\/nwjo7078","type":"journal-article","created":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T09:32:32Z","timestamp":1712223152000},"page":"730-737","source":"Crossref","is-referenced-by-count":2,"title":["Exploring the molecular mechanisms between lymphoma and myelofibrosis"],"prefix":"10.62347","volume":"16","author":[{"given":"Jun-Nuan","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"48694","published-online":{"date-parts":[[2024]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209-249.","journal-title":"CA Cancer J Clin"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1097\/CM9.0000000000001474","article-title":"Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020","volume":"134","author":"Cao","year":"2021","unstructured":"Cao W, Chen HD, Yu YW, Li N and Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl) 2021; 134: 783-791.","journal-title":"Chin Med J (Engl)"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/ajh.26050","article-title":"Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management","volume":"96","author":"Tefferi","year":"2021","unstructured":"Tefferi A. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management. Am J Hematol 2021; 96: 145-162.","journal-title":"Am J Hematol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M and Vardiman JW. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127: 2391-2405.","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s12185-019-02717-8","article-title":"Vitamin B6 deficiency is prevalent in primary and secondary myelofibrosis patients","volume":"110","author":"Yasuda","year":"2019","unstructured":"Yasuda H, Tsutsui M, Ando J, Inano T, Noguchi M, Yahata Y, Tanaka M, Tsukune Y, Masuda A, Shirane S, Misawa K, Gotoh A, Sato E, Aritaka N, Sekiguchi Y, Sugimoto K and Komatsu N. Vitamin B6 deficiency is prevalent in primary and secondary myelofibrosis patients. Int J Hematol 2019; 110: 543-549.","journal-title":"Int J Hematol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1486476","DOI":"10.1155\/2019\/1486476","article-title":"Coexistence of myeloid and lymphoid neoplasms: a single-center experience","volume":"2019","author":"Bouchla","year":"2019","unstructured":"Bouchla A, Thomopoulos T, Papageorgiou S, Tsirigotis P, Bazani E, Gkirkas K, Vasilatou D, Glezou E, Stavroulaki G, Gkontopoulos K, Dimitriadis G and Pappa V. Coexistence of myeloid and lymphoid neoplasms: a single-center experience. Adv Hematol 2019; 2019: 1486476.","journal-title":"Adv Hematol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1182\/blood-2018-04-845065","article-title":"Distinct patterns of clonal evolution in patients with concurrent myelo- and lymphoproliferative neoplasms","volume":"132","author":"Kennedy","year":"2018","unstructured":"Kennedy JA, Medeiros JJF, Dobson SM, Arruda A, Sukhai MA, Stockley T, Tierens A, Minden MD, Kamel-Reid S, Dick JE and Gupta V. Distinct patterns of clonal evolution in patients with concurrent myelo- and lymphoproliferative neoplasms. Blood 2018; 132: 2201-2205.","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/hon.2701","article-title":"Myeloproliferative and lymphoproliferative disorders: state of the art","volume":"38","author":"Rumi","year":"2020","unstructured":"Rumi E, Baratè C, Benevolo G, Maffioli M, Ricco A and Sant’Antonio E. Myeloproliferative and lymphoproliferative disorders: state of the art. Hematol Oncol 2020; 38: 121-128.","journal-title":"Hematol Oncol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1002\/ajh.25049","article-title":"Lymphoproliferative disorders in patients with chronic myeloproliferative neoplasms: a systematic review","volume":"93","author":"Marchetti","year":"2018","unstructured":"Marchetti M, Carobbio A, Capitoni E and Barbui T. Lymphoproliferative disorders in patients with chronic myeloproliferative neoplasms: a systematic review. Am J Hematol 2018; 93: 698-703.","journal-title":"Am J Hematol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"5526","DOI":"10.3390\/cancers13215526","article-title":"Proteomic profiling differentiates lymphoma patients with and without concurrent myeloproliferative neoplasia","volume":"13","author":"JM","year":"2021","unstructured":"Holst JM, Enemark MB, Pedersen MB, Lauridsen KL, Hybel TE, Clausen MR, Frederiksen H, Møller MB, Nørgaard P, Plesner TL, Hamilton-Dutoit SJ, d’Amore F, Honoré B and Ludvigsen M. Proteomic profiling differentiates lymphoma patients with and without concurrent myeloproliferative neoplasia. Cancers (Basel) 2021; 13: 5526.","journal-title":"Cancers (Basel)"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"179847","DOI":"10.1155\/2009\/179847","article-title":"Myelofibrosis-associated lymphoproliferative disease: retrospective study of 16 cases and literature review","volume":"2009","author":"Etienne","year":"2009","unstructured":"Etienne A, Gruson B, Chatelain D, Garidi R, Royer B, Sevestre H, Marolleau JP and Damaj G. Myelofibrosis-associated lymphoproliferative disease: retrospective study of 16 cases and literature review. Adv Hematol 2009; 2009: 179847.","journal-title":"Adv Hematol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1007\/s12185-013-1386-9","article-title":"Angioimmunoblastic T-cell lymphoma with intramedullary production of platelet-derived growth factor and possibly complicating myelofibrosis: report of a case with review of the literature","volume":"98","author":"Sekiguchi","year":"2013","unstructured":"Sekiguchi Y, Matsuzawa N, Shimada A, Imai H, Wakabayashi M, Sugimoto K, Nakamura N, Sawada T, Izutsu K, Takeuchi K, Ohta Y, Komatsu N and Noguchi M. Angioimmunoblastic T-cell lymphoma with intramedullary production of platelet-derived growth factor and possibly complicating myelofibrosis: report of a case with review of the literature. Int J Hematol 2013; 98: 250-257.","journal-title":"Int J Hematol"},{"key":"ref12","unstructured":"Li Q, Lin ZH, Cai YF, Teng R, Yang XI and You XF. A case of lymphoma with myelofibrosis onset and literature review. Jiangsu Med J 2018; 44: 713-715."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"34","DOI":"10.4103\/2231-0770.130343","article-title":"Simultaneous hepatosplenic T-cell lymphoma and myelofibrosis","volume":"4","author":"Gabali","year":"2014","unstructured":"Gabali AM, Jazaerly T, Chang CC, Cleveland R and Kass L. Simultaneous hepatosplenic T-cell lymphoma and myelofibrosis. Avicenna J Med 2014; 4: 34-36.","journal-title":"Avicenna J Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"4551","DOI":"10.2147\/OTT.S313428","article-title":"Simultaneous follicular lymphoma and myelofibrosis: report of a case with review of the literature","volume":"14","author":"Kong","year":"2021","unstructured":"Kong LZ, Li J, Wang RC, Kang L, Wei Q and Li Y. Simultaneous follicular lymphoma and myelofibrosis: report of a case with review of the literature. Onco Targets Ther 2021; 14: 4551-4559.","journal-title":"Onco Targets Ther"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1182\/blood-2017-10-810739","article-title":"Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1\/2 inhibitor therapy","volume":"132","author":"Porpaczy","year":"2018","unstructured":"Porpaczy E, Tripolt S, Hoelbl-Kovacic A, Gisslinger B, Bago-Horvath Z, Casanova-Hevia E, Clappier E, Decker T, Fajmann S, Fux DA, Greiner G, Gueltekin S, Heller G, Herkner H, Hoermann G, Kiladjian JJ, Kolbe T, Kornauth C, Krauth MT, Kralovics R, Muellauer L, Mueller M, Prchal-Murphy M, Putz EM, Raffoux E, Schiefer AI, Schmetterer K, Schneckenleithner C, Simonitsch-Klupp I, Skrabs C, Sperr WR, Staber PB, Strobl B, Valent P, Jaeger U, Gisslinger H and Sexl V. Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1\/2 inhibitor therapy. Blood 2018; 132: 694-706.","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Rumi E, Zibellini S, Boveri E, Cavalloni C, Riboni R, Casetti IC, Ciboddo M, Trotti C, Favaron C, Pietra D, Candido C, Ferretti VV, Cazzola M and Arcaini L. Ruxolitinib treatment and risk of B-cell lymphomas in myeloproliferative neoplasms. Am J Hematol 2019; 94: E185-E188.","DOI":"10.1002\/ajh.25489"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/s12288-020-01320-w","article-title":"The journey of primary myelofibrosis to splenic marginal zone lymphoma on the wheels of ruxolitinib","volume":"37","author":"Dass","year":"2021","unstructured":"Dass J, Langer S, Kotwal J and Gupta N. The journey of primary myelofibrosis to splenic marginal zone lymphoma on the wheels of ruxolitinib. Indian J Hematol Blood Transfus 2021; 37: 186-188.","journal-title":"Indian J Hematol Blood Transfus"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1182\/blood-2019-01-897637","article-title":"Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy","volume":"133","author":"Pemmaraju","year":"2019","unstructured":"Pemmaraju N, Kantarjian H, Nastoupil L, Dupuis M, Zhou L, Pierce S, Patel KP, Masarova L, Cortes J and Verstovsek S. Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy. Blood 2019; 133: 2348-2351.","journal-title":"Blood"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/bjh.16576","article-title":"Myelofibrosis biology and contemporary management","volume":"191","author":"Gangat","year":"2020","unstructured":"Gangat N and Tefferi A. Myelofibrosis biology and contemporary management. Br J Haematol 2020; 191: 152-170.","journal-title":"Br J Haematol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1158\/2159-8290.CD-20-0839","article-title":"Clinical and biological subtypes of B-cell lymphoma revealed by microenvironmental signatures","volume":"11","author":"Kotlov","year":"2021","unstructured":"Kotlov N, Bagaev A, Revuelta MV, Phillip JM, Cacciapuoti MT, Antysheva Z, Svekolkin V, Tikhonova E, Miheecheva N, Kuzkina N, Nos G, Tabbo F, Frenkel F, Ghione P, Tsiper M, Almog N, Fowler N, Melnick AM, Leonard JP, Inghirami G and Cerchietti L. Clinical and biological subtypes of B-cell lymphoma revealed by microenvironmental signatures. Cancer Discov 2021; 11: 1468-1489.","journal-title":"Cancer Discov"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1110765","DOI":"10.3389\/fbioe.2023.1110765","article-title":"JAK\/STAT pathway: extracellular signals, diseases, immunity, and therapeutic regimens","volume":"11","author":"Hu","year":"2023","unstructured":"Hu Q, Bian Q, Rong D, Wang L, Song J, Huang HS, Zeng J, Mei J and Wang PY. JAK\/STAT pathway: extracellular signals, diseases, immunity, and therapeutic regimens. Front Bioeng Biotechnol 2023; 11: 1110765.","journal-title":"Front Bioeng Biotechnol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s11899-020-00571-8","article-title":"Myeloproliferative neoplasms in children, adolescents, and young adults","volume":"15","author":"Kucine","year":"2020","unstructured":"Kucine N. Myeloproliferative neoplasms in children, adolescents, and young adults. Curr Hematol Malig Rep 2020; 15: 141-148.","journal-title":"Curr Hematol Malig Rep"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41408-019-0236-2","article-title":"Myelofibrosis in 2019: moving beyond JAK2 inhibition","volume":"9","author":"Schieber","year":"2019","unstructured":"Schieber M, Crispino JD and Stein B. Myelofibrosis in 2019: moving beyond JAK2 inhibition. Blood Cancer J 2019; 9: 74.","journal-title":"Blood Cancer J"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1182\/blood.2019000943","article-title":"Leukemia secondary to myeloproliferative neoplasms","volume":"136","author":"AJ","year":"2020","unstructured":"Dunbar AJ, Rampal RK and Levine R. Leukemia secondary to myeloproliferative neoplasms. Blood 2020; 136: 61-70.","journal-title":"Blood"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Dunbar AJ, Kim D, Lu M, Farina M, Bowman RL, Yang JL, Park Y, Karzai A, Xiao W, Zaroogian Z, O’Connor K, Mowla S, Gobbo F, Verachi P, Martelli F, Sarli G, Xia L, Elmansy N, Kleppe M, Chen Z, Xiao Y, McGovern E, Snyder J, Krishnan A, Hill C, Cordner K, Zouak A, Salama ME, Yohai J, Tucker E, Chen J, Zhou J, McConnell T, Migliaccio AR, Koche R, Rampal R, Fan R, Levine RL and Hoffman R. CXCL8\/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis. Blood 2023; 141: 2508-2519.","DOI":"10.1182\/blood.2022015418"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1196817","DOI":"10.3389\/fonc.2023.1196817","article-title":"Mutations, inflammation and phenotype of myeloproliferative neoplasms","volume":"13","author":"Hermouet","year":"2023","unstructured":"Hermouet S. Mutations, inflammation and phenotype of myeloproliferative neoplasms. Front Oncol 2023; 13: 1196817.","journal-title":"Front Oncol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1002\/cncr.34205","article-title":"Defining disease modification in myelofibrosis in the era of targeted therapy","volume":"128","author":"Pemmaraju","year":"2022","unstructured":"Pemmaraju N, Verstovsek S, Mesa R, Gupta V, Garcia JS, Scandura JM, Oh ST, Passamonti F, Döhner K and Mead AJ. Defining disease modification in myelofibrosis in the era of targeted therapy. Cancer 2022; 128: 2420-2432.","journal-title":"Cancer"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3390\/biom13010119","article-title":"The role of JAK\/STAT pathway in fibrotic diseases: molecular and cellular mechanisms","volume":"13","author":"Liu","year":"2023","unstructured":"Liu J, Wang F and Luo F. The role of JAK\/STAT pathway in fibrotic diseases: molecular and cellular mechanisms. Biomolecules 2023; 13: 119.","journal-title":"Biomolecules"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.3390\/molecules28052195","article-title":"Baricitinib attenuates bleomycin-induced pulmonary fibrosis in mice by inhibiting TGF-β1 signaling pathway","volume":"28","author":"Gu","year":"2023","unstructured":"Gu S, Liang J, Zhang J, Liu Z, Miao Y, Wei Y, Li S, Gu J, Cui Y, Xiao T, Li X and Yang C. Baricitinib attenuates bleomycin-induced pulmonary fibrosis in mice by inhibiting TGF-β1 signaling pathway. Molecules 2023; 28: 2195.","journal-title":"Molecules"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"100224","DOI":"10.1016\/j.aohep.2020.06.010","article-title":"STAT3: a key regulator in liver fibrosis","volume":"21","author":"Zhao","year":"2021","unstructured":"Zhao J, Qi YF and Yu YR. STAT3: a key regulator in liver fibrosis. Ann Hepatol 2021; 21: 100224.","journal-title":"Ann Hepatol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"696542","DOI":"10.3389\/fcell.2021.696542","article-title":"Signaling pathways involved in diabetic renal fibrosis","volume":"9","author":"Zhang","year":"2021","unstructured":"Zhang Y, Jin D, Kang X, Zhou R, Sun Y, Lian F and Tong X. Signaling pathways involved in diabetic renal fibrosis. Front Cell Dev Biol 2021; 9: 696542.","journal-title":"Front Cell Dev Biol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.bbcan.2014.04.003","article-title":"Signaling pathways involved in MDSC regulation","volume":"1846","author":"Trikha","year":"2014","unstructured":"Trikha P and Carson WE 3rd. Signaling pathways involved in MDSC regulation. Biochim Biophys Acta 2014; 1846: 55-65.","journal-title":"Biochim Biophys Acta"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.1038\/s41375-020-0767-3","article-title":"miR-146a rs2431697 identifies myeloproliferative neoplasm patients with higher secondary myelofibrosis progression risk","volume":"34","author":"Ferrer-Mar&#xED","year":"2020","unstructured":"Ferrer-Marín F, Arroyo AB, Bellosillo B, Cuenca EJ, Zamora L, Hernández-Rivas JM, Hernández-Boluda JC, Fernandez-Rodriguez C, Luño E, García Hernandez C, Kerguelen A, Fiallo-Suárez DV, Gómez-Casares MT, Ayala R, Vélez P, Boqué C, García-Gutierrez V, Arrizabalaga B, Estrada N, Cifuentes R, Arcas I, de Los Reyes-García AM, Besses C, Vicente V, Alvarez-Larrán A, Teruel-Montoya R, González-Conejero R and Martínez C; GEMFIN Group. miR-146a rs2431697 identifies myeloproliferative neoplasm patients with higher secondary myelofibrosis progression risk. Leukemia 2020; 34: 2648-2659.","journal-title":"Leukemia"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1134661","DOI":"10.3389\/fimmu.2023.1134661","article-title":"NF-κB in monocytes and macrophages - an inflammatory master regulator in multitalented immune cells","volume":"14","author":"Mussbacher","year":"2023","unstructured":"Mussbacher M, Derler M, Basílio J and Schmid JA. NF-κB in monocytes and macrophages - an inflammatory master regulator in multitalented immune cells. Front Immunol 2023; 14: 1134661.","journal-title":"Front Immunol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"5347","DOI":"10.1038\/s41467-022-32928-3","article-title":"Interleukin-1 contributes to clonal expansion and progression of bone marrow fibrosis in JAK2V617F-induced myeloproliferative neoplasm","volume":"13","author":"Rahman","year":"2022","unstructured":"Rahman MF, Yang Y, Le BT, Dutta A, Posyniak J, Faughnan P, Sayem MA, Aguilera NS and Mohi G. Interleukin-1 contributes to clonal expansion and progression of bone marrow fibrosis in JAK2V617F-induced myeloproliferative neoplasm. Nat Commun 2022; 13: 5347.","journal-title":"Nat Commun"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1182\/blood.2022017326","article-title":"IL-13\/IL-4 signaling contributes to fibrotic progression of the myeloproliferative neoplasms","volume":"140","author":"Melo-Cardenas","year":"2022","unstructured":"Melo-Cardenas J, Bezavada L, Crawford JC, Gurbuxani S, Cotton A, Kang G, Gossett J, Marinaccio C, Weinberg R, Hoffman R, Migliaccio AR, Zheng Y, Derecka M, Rinaldi CR and Crispino JD. IL-13\/IL-4 signaling contributes to fibrotic progression of the myeloproliferative neoplasms. Blood 2022; 140: 2805-2817.","journal-title":"Blood"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/cancers12010019","article-title":"STAT3 activation and oncogenesis in lymphoma","volume":"12","author":"Zhu","year":"2019","unstructured":"Zhu F, Wang KB and Rui L. STAT3 activation and oncogenesis in lymphoma. Cancers (Basel) 2019; 12: 19.","journal-title":"Cancers (Basel)"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1182\/blood.2020004918","article-title":"MYD88 L265P elicits mutation-specific ubiquitination to drive NF-κB activation and lymphomagenesis","volume":"137","author":"Yu","year":"2021","unstructured":"Yu X, Li W, Deng Q, Liu H, Wang X, Hu H, Cao Y, Xu-Monette ZY, Li L, Zhang M, Lu Z, Young KH and Li Y. MYD88 L265P elicits mutation-specific ubiquitination to drive NF-κB activation and lymphomagenesis. Blood 2021; 137: 1615-1627.","journal-title":"Blood"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1158\/0008-5472.CAN-16-0786","article-title":"CXCL-8\/IL8 produced by diffuse large B-cell lymphomas recruits neutrophils expressing a proliferation-inducing ligand APRIL","volume":"77","author":"Manfroi","year":"2017","unstructured":"Manfroi B, McKee T, Mayol JF, Tabruyn S, Moret S, Villiers C, Righini C, Dyer M, Callanan M, Schneider P, Tzankov A, Matthes T, Sturm N and Huard B. CXCL-8\/IL8 produced by diffuse large B-cell lymphomas recruits neutrophils expressing a proliferation-inducing ligand APRIL. Cancer Res 2017; 77: 1097-1107.","journal-title":"Cancer Res"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1080\/15384047.2019.1683332","article-title":"β-TrCP1 promotes cell proliferation via TNF-dependent NF-κB activation in diffuse large B cell lymphoma","volume":"21","author":"Cai","year":"2020","unstructured":"Cai N, Chen Z, Huang Y, Shao S, Yu H, Wang Y and He S. β-TrCP1 promotes cell proliferation via TNF-dependent NF-κB activation in diffuse large B cell lymphoma. Cancer Biol Ther 2020; 21: 241-247.","journal-title":"Cancer Biol Ther"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1038\/s41375-019-0379-y","article-title":"Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFκB signaling","volume":"33","author":"Fisher","year":"2019","unstructured":"Fisher DAC, Miner CA, Engle EK, Hu H, Collins TB, Zhou A, Allen MJ, Malkova ON and Oh ST. Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFκB signaling. Leukemia 2019; 33: 1978-1995.","journal-title":"Leukemia"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"8586354","DOI":"10.1155\/2019\/8586354","article-title":"Tumor microenvironment in diffuse large B-cell lymphoma: role and prognosis","volume":"2019","author":"Cioroianu","year":"2019","unstructured":"Cioroianu AI, Stinga PI, Sticlaru L, Cioplea MD, Nichita L, Popp C and Staniceanu F. Tumor microenvironment in diffuse large B-cell lymphoma: role and prognosis. Anal Cell Pathol (Amst) 2019; 2019: 8586354.","journal-title":"Anal Cell Pathol (Amst)"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1080\/10428194.2018.1516881","article-title":"Mesenchymal stem cells in myeloproliferative disorders - focus on primary myelofibrosis","volume":"60","author":"Selicean","year":"2019","unstructured":"Selicean SE, Tomuleasa C, Grewal R, Almeida-Porada G and Berindan-Neagoe I. Mesenchymal stem cells in myeloproliferative disorders - focus on primary myelofibrosis. Leuk Lymphoma 2019; 60: 876-885.","journal-title":"Leuk Lymphoma"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Varricchio L, Iancu-Rubin C, Upadhyaya B, Zingariello M, Martelli F, Verachi P, Clementelli C, Denis JF, Rahman AH, Tremblay G, Mascarenhas J, Mesa RA, O’Connor-McCourt M, Migliaccio AR and Hoffman R. TGF-β1 protein trap AVID200 beneficially affects hematopoiesis and bone marrow fibrosis in myelofibrosis. JCI Insight 2021; 6: e145651.","DOI":"10.1172\/jci.insight.145651"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/ajh.25047","article-title":"The spleen of patients with myelofibrosis harbors defective mesenchymal stromal cells","volume":"93","author":"MA","year":"2018","unstructured":"Avanzini MA, Abbonante V, Catarsi P, Dambruoso I, Mantelli M, Poletto V, Lenta E, Guglielmelli P, Croce S, Cobianchi L, Jemos B, Campanelli R, Bonetti E, Di Buduo CA, Salmoiraghi S, Villani L, Massa M, Boni M, Zappatore R, Iurlo A, Rambaldi A, Vannucchi AM, Bernasconi P, Balduini A, Barosi G and Rosti V; AGIMM Investigators. The spleen of patients with myelofibrosis harbors defective mesenchymal stromal cells. Am J Hematol 2018; 93: 615-622.","journal-title":"Am J Hematol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"869242","DOI":"10.1155\/2015\/869242","article-title":"Cytokine regulation of microenvironmental cells in myeloproliferative neoplasms","volume":"2015","author":"Hoermann","year":"2015","unstructured":"Hoermann G, Greiner G and Valent P. Cytokine regulation of microenvironmental cells in myeloproliferative neoplasms. Mediators Inflamm 2015; 2015: 869242.","journal-title":"Mediators Inflamm"},{"key":"ref47","unstructured":"Sakatoku K, Takeoka Y, Araki T, Miura A, Fujitani Y, Yamamura R, Miyagi Y, Senzaki H and Ohta K. Lymphocyte-depleted classical Hodgkin lymphoma accompanied by myelofibrosis. Rinsho Ketsueki 2017; 58: 772-775."},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Hoard R, Shahin G, Andreca FD and Osswald M. Gamma-delta T-cell lymphoma following allogeneic stem cell transplant for primary myelofibrosis. Cureus 2020; 12: e10301.","DOI":"10.7759\/cureus.10301"},{"key":"ref49","unstructured":"Matsuura M, Koshiishi M, Suzuki J, Suzuki M, Kawashima I, Nakajima K and Kirito K. Angioimmunoblastic T-cell lymphoma complicated with various autoimmune abnormalities and myelofibrosis. Rinsho Ketsueki 2020; 61: 110-115."},{"key":"ref50","unstructured":"Sekiguchi Y, Shirane S, Shimada A, Ichikawa K, Wakabayashi M, Sugimoto K, Tomita S, Izumi H, Nakamura N, Sawada T, Ohta Y, Komatsu N and Noguchi M. Peripheral T cell lymphoma, not otherwise specified with myelofibrosis: report of a case with review of the literature. Int J Clin Exp Pathol 2015; 8: 4186-4203."},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Jain A, Rajpal S, Sachdeva MUS and Malhotra P. Numb chin syndrome as a presenting symptom of diffuse large B-cell lymphoma with secondary myelofibrosis. BMJ Case Rep 2018; 2018: bcr2017221245.","DOI":"10.1136\/bcr-2017-221245"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"7426739","DOI":"10.1155\/2018\/7426739","article-title":"Chronic lymphocytic leukemia and myelofibrosis","volume":"2018","author":"Darawshy","year":"2018","unstructured":"Darawshy F, Ben-Yehuda A, Atlan K and Rund D. Chronic lymphocytic leukemia and myelofibrosis. Case Rep Hematol 2018; 2018: 7426739.","journal-title":"Case Rep Hematol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"798","DOI":"10.3892\/mco.2017.1398","article-title":"Intravascular large B-cell lymphoma associated with myelofibrosis: a case report","volume":"7","author":"Choi","year":"2017","unstructured":"Choi JG, Cho HH, Kang SR, Jang SM, Yoo EH, Cho HJ, Kim SM and Cho DY. Intravascular large B-cell lymphoma associated with myelofibrosis: a case report. Mol Clin Oncol 2017; 7: 798-802.","journal-title":"Mol Clin Oncol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.3892\/ol.2015.3438","article-title":"Hodgkin’s lymphoma associated with myelofibrosis: a case report","volume":"10","author":"Fu","year":"2015","unstructured":"Fu R, Yu H, Wu YH, Liu H and Shao ZH. Hodgkin’s lymphoma associated with myelofibrosis: a case report. Oncol Lett 2015; 10: 1551-1554.","journal-title":"Oncol Lett"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/path.5680","article-title":"TGF-β as a driver of fibrosis: physiological roles and therapeutic opportunities","volume":"254","author":"Budi","year":"2021","unstructured":"Budi EH, Schaub JR, Decaris M, Turner S and Derynck R. TGF-β as a driver of fibrosis: physiological roles and therapeutic opportunities. J Pathol 2021; 254: 358-373.","journal-title":"J Pathol"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.3324\/haematol.2020.253708","article-title":"Busy signal: platelet-derived growth factor activation in myelofibrosis","volume":"105","author":"Marneth","year":"2020","unstructured":"Marneth AE and Mullally A. Busy signal: platelet-derived growth factor activation in myelofibrosis. Haematologica 2020; 105: 1988-1990.","journal-title":"Haematologica"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.3324\/haematol.2019.226332","article-title":"Platelet-derived growth factor receptor β activation and regulation in murine myelofibrosis","volume":"105","author":"Kramer","year":"2020","unstructured":"Kramer F, Dernedde J, Mezheyeuski A, Tauber R, Micke P and Kappert K. Platelet-derived growth factor receptor β activation and regulation in murine myelofibrosis. Haematologica 2020; 105: 2083-2094.","journal-title":"Haematologica"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/s41419-022-04932-4","article-title":"GLI1 activates pro-fibrotic pathways in myelofibrosis fibrocytes","volume":"13","author":"Manshouri","year":"2022","unstructured":"Manshouri T, Veletic I, Li P, Yin CC, Post SM, Verstovsek S and Estrov Z. GLI1 activates pro-fibrotic pathways in myelofibrosis fibrocytes. Cell Death Dis 2022; 13: 481.","journal-title":"Cell Death Dis"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Malara A, Abbonante V, Zingariello M, Migliaccio A and Balduini A. Megakaryocyte contribution to bone marrow fibrosis: many arrows in the quiver. Mediterr J Hematol Infect Dis 2018; 10: e2018068.","DOI":"10.4084\/mjhid.2018.068"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1177\/0394632016644447","article-title":"Role of mast cells in fibrosis of classical Hodgkin lymphoma","volume":"29","author":"Nakayama","year":"2016","unstructured":"Nakayama S, Yokote T, Hiraoka N, Nishiwaki U, Hanafusa T, Nishimura Y and Tsuji M. Role of mast cells in fibrosis of classical Hodgkin lymphoma. Int J Immunopathol Pharmacol 2016; 29: 603-611.","journal-title":"Int J Immunopathol Pharmacol"}],"container-title":["American Journal of Translational Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajtr\/16\/3\/ajtr0154161.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:52:26Z","timestamp":1766022746000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajtr\/16\/3\/ajtr0154161.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":61,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.62347\/nwjo7078","relation":{},"ISSN":["1943-8141"],"issn-type":[{"value":"1943-8141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]}}}